Name	**Larry Wonshin Kwak, M.D., Ph. D.**
Current Position & Affiliation	Vice President and Deputy Director, City of Hope Comprehensive Cancer Center, and Director, Toni Stephenson Lymphoma Center Duarte, CA Scientific Founder, Pepromene Bio, Inc., Irvine, CA
Country	United States
Major Field	Invention of immune therapies for blood cancers

Educational Background

Northwestern University, BS, 1979; MD, 1982; PhD Tumor Cell Biology, 1984
Stanford University, Internship/Residency Internal medicine; Fellowship medical oncology, 1984-91

Professional Experience

Senior Investigator, Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 1992-2004
Professor and Chairman, Dept. of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, 2004-2015
Deputy Director, City of Hope Comprehensive Cancer Center, Duarte, CA, 2015-present

Other Experience and Professional Memberships

Member, Experimental Immunology Study Section, National Institutes of Health, 1996-2000
Editorial Board, Blood, 1997-2002
Scientific Advisory Board, Multiple Myeloma Research Foundation, 2000-2004
Editorial Board, Journal of Clinical Oncology, 2006-2009
Cellular, Tissue and Gene Therapies Advisory Committee, Food and Drug Administration, 2006-2018
TIME 100 (Named by TIME magazine as one of the 100 most influential persons in the world), 2010
National Medical and Scientific Affairs Committee, Leukemia & Lymphoma Society, 2014-present
Ho-Am Prize in Medicine, 2016

Main Scientific Publications

1. **Kwak LW**, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327(17):1209-15, 1992.
2. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, **Kwak LW**. Complete molecular remissions induced by patient-specific vaccination plus

granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med 5(10):1171-7, 1999.

3. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, **Kwak LW**. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298:1025-9, 2002.
4. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, and **Kwak LW.**Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 29(20):2787-94, 2011
5. Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, **Kwak LW**. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw9414
6. Szymura SJ, Wang L, Zhang T, Cha SC, Song J, Dong Z, Anderson A, Oh E, Lee V, Wang Z, Parshottam S, Rao S, Olsem JB, Crumpton BN, Lee HC, Manasanch EE, Neelapu S, Kwak LW, Thomas SK. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat Commun. 2024 Aug 11;15(1):6874.